Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
Date:4/28/2009

oduct candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a marketing license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a marketing license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
2. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
3. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
4. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
5. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
8. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
10. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... le 4 mai 2015  Lors du salon ... (hall 5, stand 5510), North Star Imaging Europe ... à rayons X spécialement conçu pour la métrologie. ... les rayons X, la CXMM 50, a été ... de métrologie destiné à offrir à l,utilisateur un ...
(Date:5/4/2015)... HAVEN, Conn. , May 4, 2015 /PRNewswire/ ... chosen by the American Optometric Association (AOA) to ... delivery and outcomes for the millions of patients ... Measures and Outcomes Registry for Eyecare (MORE) ... will securely facilitate efficient secondary uses of essential ...
(Date:5/4/2015)... EspeRare today announced that the ... Designation (ODD) for rimeporide, its lead compound for the ... rare, life-threatening disease affecting boys early in childhood that ... most common and serious form of paediatric muscular dystrophies. ... inhibitor, originally developed by Merck Serono in the intended ...
Breaking Medicine Technology:NSI sera présente lors du salon Control 2015, du 5 au 8 mai à Stuttgart, en Allemagne : axer la GMAO vers une nouvelle dimension 2American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... May 04, 2015 World T.E.A.M. Sports’ ... cycle ride in the last decade arrived in this ... miles in two days from the Pentagon in Arlington, ... 581 registered disabled and able-bodied participants work together to ... recognizes and honors the commitment and sacrifices by military ...
(Date:5/4/2015)... 04, 2015 For partners who’d like ... lubricant -- Astroglide TTC™ (Trying to Conceive) . ... alter pH levels, Astroglide TTC™ is specially formulated to ... to the Centers for Disease Control, an average of ... pregnant or sustaining a pregnancy, and over 7.4 ...
(Date:5/4/2015)... 2015 Scanmarket, a leading provider of ... included in the just-released Spend Matters “50 to Know” ... Matters " 50 To Know " listing is a ... commitment to providing comprehensive, easy-to-use strategic sourcing solutions to ... are many well-established and respected companies on this list, ...
(Date:5/4/2015)... “ Food Cost Calculator ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... manage and efficiently calculate food costs. , The restaurant industry ... the industry has an estimated 1.8 trillion dollar impact on ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
Breaking Medicine News(10 mins):Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Scanmarket Selected to Spend Matters "50 To Know" List of Companies in Procurement Sector. 2Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4
... women with early-stage breast cancer have similar survival rates with ... with mastectomy, a new study conducted at the University of ... 15,000 patients listed in a nationwide cancer registry will be ... Sept. 8-11 in San Francisco. Steven J. Feigenberg, ...
... safety concerns may prevent children from getting good exercise, ... that examined how families use neighborhood parks. ... monitored too closely by hovering "helicopter" parents were less ... "It,s a catch-22 for today,s parents, unfortunately. ...
... 7 (HealthDay News) -- Although it is often said that ... in a person,s life, the risk of suicide is high ... United States, suicide is the second leading cause of death ... Dasey-Morales, a psychologist from Wichita State University. Dasey-Morales advised ...
... 7 (HealthDay News) -- Babies living in bilingual homes have ... to different languages than infants living where just one language ... infants living in bilingual (English and Spanish) and monolingual homes ... in bilingual homes remained flexible to languages until they were ...
... medical schools offer their students poor health insurance coverage for ... practice that imperils the well-being of our nation,s future doctors ... JAMA today [Sept. 7]. In the first ... are faculty physicians at the Harvard-affiliated Cambridge Health Alliance (CHA) ...
... Reporter , TUESDAY, Sept. 6 (HealthDay News) -- The medical ... -- is exhausted, emotionally spent and likely stressed out about ... our trainees are burned out," said study leader Dr. Colin ... the Mayo Clinic in Rochester, Minn. Higher levels of ...
Cached Medicine News:Health News:Young women with early breast cancer have similar survival with breast conservation, mastectomy 2Health News:Young women with early breast cancer have similar survival with breast conservation, mastectomy 3Health News:Helicopter parents can impede child’s ability to play 2Health News:Teens, College-Age Youth at High Risk of Suicide, Expert Says 2Health News:Bilingual Homes Help Babies Exercise Their Brain: Study 2Health News:Most med schools offer students poor mental health coverage, imperiling students, patients 2Health News:Burnout, Dissatisfaction Seem Rampant Among Medical Residents 2Health News:Burnout, Dissatisfaction Seem Rampant Among Medical Residents 3
Provides a combination of concentrated cold / hot and compression for the neck...
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery....
Provides a combination of concentrated cold / hot and compression for the shoulder...
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Medicine Products: